<SEC-DOCUMENT>0001193125-14-439081.txt : 20141210
<SEC-HEADER>0001193125-14-439081.hdr.sgml : 20141210
<ACCEPTANCE-DATETIME>20141210171259
ACCESSION NUMBER:		0001193125-14-439081
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20141210
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20141210
DATE AS OF CHANGE:		20141210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		141278719

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d835467d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;10, 2014 (December 10, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;10, 2014,
ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that the U.S. Food and Drug Administration, Office of Orphan Drug Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever post-exposure
to Ebola virus. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9
&#151; Financial Statements and Exhibits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Press Release titled &#147;ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola&#148; dated December 10, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December&nbsp;10, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name: Christopher Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title: &nbsp;&nbsp;SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Press Release titled &#147;ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola&#148; dated December 10, 2014.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d835467dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g835467snap0002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION FOR RNAPC2 AS A POTENTIAL TREATMENT FOR EBOLA
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>rNAPc2 Previously Demonstrated Post-Exposure Efficacy in NHP Models of Ebola HFV </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>rNAPc2 Previously Tested in Over 700 Human Patients in Nine Phase 1 and 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cardiovascular Disease Clinical Trials </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>rNAPc2
Potentially Inhibits the Human Body&#146;s Catastrophic Response to Hemorrhagic </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fever Viruses Like Ebola </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, December&nbsp;10, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted
therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted orphan drug designation to rNAPc2 as a potential treatment of viral hemorrhagic fever
post-exposure to Ebola virus. The drug candidate has previously demonstrated post-exposure efficacy in non-human primate models of Ebola hemorrhagic fever virus (HFV). rNAPc2 was originally developed as a cardiovascular therapy for thrombosis and
other indications. As a result, it has an extensive human clinical record, and has been safely tested in over 700 human patients in nine Phase 1 and 2 clinical trials for cardiovascular disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug designation is granted by the FDA Office of Orphan Products Development to novel drugs or biologics that treat rare diseases or conditions
affecting fewer than 200,000 individuals in the U.S. The designation provides the drug developer with a seven-year period of U.S. marketing exclusivity upon marketing approval, as well as certain financial incentives that can help support its
development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About rNAPc2 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">rNAPc2 (Recombinant
Nematode Anticoagulation Protein c2) is a potent and selective inhibitor of tissue factor (TF), the protein responsible for initiating the extrinsic coagulation pathway, the primary coagulation mechanism in humans. The rationale for rNAPc2 as a HFV
therapy arises from the role of TF in HFV mediated disseminated intravascular coagulation (DIC), an often fatal complication of the HFV disease syndrome that leads to spontaneous hemorrhage. Previous research studies have shown that abnormal
activation of TF is a common element of the host response to infection from Ebola, Marburg and other HFVs. This activation of TF results in a systemic consumption coagulopathy and related inflammation, which is believed to be partially responsible
for the high morbidity and mortality caused by these infections. rNAPc2 was identified as a potential therapeutic for HFV infection because of its unique mechanism of action in inhibiting TF. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Previously, pilot studies of rNAPc2 in non-human primates demonstrated potential efficacy against two of the most
deadly known HFVs, Ebola and Marburg. The results of these studies demonstrated that, when administered as a post-exposure therapy, rNAPc2 showed evidence of efficacy in improving survival and inhibiting the DIC process. Additionally, in these
studies, rNAPc2 demonstrated anti-inflammatory and anti-viral properties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA is currently exploring options for the development of rNAPc2 including
seeking development partners, out-licensing the compound and applying for grant or government funding. ARCA is not actively developing rNAPc2 for any indications and has no plans to begin such development without securing a partnership, an
out-licensing agreement or receiving grant or government funding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>rNAPc2 Publications </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Geisbert TW, Hensley LE, Jahrling PB, Larsen T, Geisbert JB, Paragas J, Young HA, Fredeking TM, Rote WE, Vlasuk GP. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study
in rhesus monkeys. Lancet. 2003;362(9400):1953-8. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, Fritz EA, Larsen T, Hensley LE. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant
protein c2. J Infect Dis. 2007;196 Suppl 2:S372-81. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations
that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF
trial. For more information please visit <U>www.arcabiopharma.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, the potential for rNAPc2 to be developed for, or to effectively treat hemorrhagic fever viruses, including Ebola, the potential for genetic variations to predict
individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted atrial fibrillation
prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the
Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to
the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without
limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g835467snap0002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g835467snap0002.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$L`T0,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/WB\0>(-*\,:7<ZQK%TMK96JY8XW2RNQ"QP6\0YFG=RJJH]
M<DA02/'SS/LKX;RZMF>;8F.&PU!;:.I4EHHTZ4+IU*DFTHQ75WDU&[75@L%B
M,=B(8;"T^:I)^D8KK*3^S%)7;^23=D_E_5?VC];EN67P_P"'M-@M%8A&U=KN
M]N95'1FBLKFV2W.!G:'FQ_>..?YWS/QZS?VTO[)R7!X;"Q;Y?KKK5ZTXK9\M
M"MAX0;_EYI\O5Z'WN%X(PO(OK6+JSJ:7=)0IPB].LXU')+57]V^EET((_CUX
M_8(?[)\+!67<N+#6#D`E3S_;@'!4CKU%>:_';C*R<,IRBTDFFZ&-V?DL?OHU
M:_K8W_U,RA?\Q.+;B[-*5+\'[!OJOL]2Q-\<_'\`'_$I\,<QQR#.GZN!M=%8
M<#72>`?3M53\<^,Z3BGE646<8R_W?&K1QYO^@]]U_P`/LH\'9,_^7^,C9M7Y
MZ32L^O\`L\;;;-JWGUH2?M">.;611/H_A=D&TNJ6FK1O@@-MW-K#^6VT]T;Z
M<'!'QXXLC)1JY5E,9*UX.CC(/O;F^NRY7;O!ZZ693X)RQI\F(Q34?[]'[[>Q
MU7H_6Q[/\._C!I'CB8:7<VIT;7?+9TLWF$]M>+&F^4V5P40M(JAF,3H&"J2"
MP!Q^N\#>*66\6UO[-Q6&_LC.5%RA1E452CB%%7D\/5<8-SBKN5*4>=13<7-)
MM?*YSPW7RN#Q%&I]9PB:3ER\LZ=W9<\4VK/1<R=KNS2T/8:_4SYH*`"@#EX_
M&GA67QA/X`CUNR;QC:Z%%XEN-`5G-[#H<MW]@CU!_D\L1FZVILW^8`Z,4".K
M,E)7Y4U==.OW#Y6H\UK1O9/^O0ZBF(*`/+[CXV_!VSU2^T2\^*7P_L=7TN[F
ML-0TV^\6Z'97EG>VTAAN+6X@NKZ-HYXI5*NA&5(YQ4<\$VN97CNNUBW3J1M[
MC7R^:_,;=_''X+V,?FW7Q:^&T$:C.3XW\-MQQC"IJ1)X(Z"GSP3MS)/M?Y?F
M@5.HVDH/RTL+HWQO^#?B&<6FB?%/X?ZE=,P1+6U\7:$]R[DD!8X/MP>1B0<!
M5-"G!Z*2OT5]?N&Z52-KP:OY?U;YGJ`(8!E(96`*L"""",@@CJ".]49BT`-=
MTB1I)&6..-6=W=@B(B`LS,S$!55022<``4;>5@/#O$/[2_P&\+W[:5JWQ1\+
MG4XSMDT_2;F?Q%>1,,922W\/6]\\;@G!5E!!X(R*S=6G&WOKY._Y;&BI5'M%
MJW?3\'8PXOVN?V<7G2UD^*>BV$[_`'(]7L-?T3('0[M7TBV4#D=2.H]:%5IW
MMS)./?3\[![*HE\.GR_+<]>\)?$+P+X]BN9O!7B_PYXJ2R$1O/[!U>QU-[/S
M]X@^UQ6LSO:^9Y4FWS57=Y;8^Z:J,XR^%WMTZ_=V(<91W3CVNK'8U0@H`Y=/
M&OA5_&,OP_36[)O&4&@Q^)IM`#2?;8]"DO#81W['R_*V&Z`3R_,\P!E<H$8,
M5S*_+?5=!\K4>:WNWM?S.HIB"@`H`^/?VC;ZZF\2Z!HX=OLEKHG]H)$"=IN+
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M\*FO>I]+>\E*$ENI6OJG;I;[P#&MU;S7$#+I]AH5EJ-YN&`[VUIAK,%O^6DU
MRFP\9`9CD8Q7T>*X$<,9AZM>ARX#`Y3AL9B9\MN:5.C[M%-I>_6K)4FMXQ<W
MRKEN<%+.OW<X4IWKU<34I4[/X4YMJ;BOLQA[VKU:2N]3R36_"LL5L=3O4$*W
M3N]K'M*37S%R9&B0Y*6BG<#)D@\+'EL[?R_-.'*U'#O,,9"5".*<YT8-6GB'
MS>].FFDXT(RLG6M;FO"%[-Q^DPV/A*HJ%*2DZ7*I2O94_=5HS:O>;5K+>-KR
M:6C\UM)[K0M:T[4K0M#<6%_:W,3(Q7;)%,C@`C^!EX(YR&(QBOF\LQF)RS,<
M'BJ$G2KX#$4:U&:T<)0J)I6O=I:Q?3E;C=GI5Z,,5AZU*I&\:D)0FG;:2Y;V
M[I]5UM):ZGZ7HVY%;&W<JMCTR`<?A7^AT)<T(2VYHIV]5<_")+EDX_RMK[M!
MU4(HZGJ5EHVFW^K:E<)::=I=E=:A?74I"QV]G90/<7,SD]%2&-V/^[2;44WL
MH_H"6R7R1^%^F_&CQ3X=_:G\.?'3Q5:WFDZ-X\O8;^UCN@Q63X6:[-/X;T^2
M-<C,-KI]E'<J&SB6P#_Q`UQ*<U4B^DM4D]-;]]%VZ7:[ZG<X1=-PCKRJRMW6
MMO6^Y^[B.CHKQLK(RJZ.A#(R,`5964X*D$$$<8KN.&UM-K=!U`'RU^U3\,/`
M'B/X-?$G6]4\):!-KVD>&M4UO3=>72K.+6;34[&%KF&X74HHEN&#.I61&D*R
M*[!@<\958KV<]+6U^[7]#6BY*<8IV3Z?\#Y6N?!?_!/#X?>"?%OB7XAZEXH\
M+Z)XAN-!TO0ETA-9TVTU*VL6U&XU);N>*TNXI(OM#):0H)2A95#!2-YSS8=)
MS>GPJZ-J\G%12=KM_A_PY^@OQI_9J^%'Q&\"Z]IQ\%>&M&URUTJ^N?#^OZ-H
MNGZ7J&F:I;6SRV<GG6-O&;FT,T:)+;S"1&C9L`.%9>J=.+3M&S2TMI\K^>S\
MFS&%246M;J^M_DNK6R6E]$?#/[`/QN\6KXVF^#/B'5+[6/#^H:/J6H>&TU&X
MEN[CP_J6BJEQ=6-I/.SNNEW%D;EC;EMD4MLK1!?-D#88>33<;Z;)>=F]UY+S
MZ&U:"Y;I6:>_X:_T_P`S]8O$.OZ1X5T+5O$FOWT.FZ+H6GW6IZG?3MMBMK.S
MB:::0]V;:I"HH+.Q55!9@#U-J*OT7](Y4FVHI:O1(_)&/QM\4OVZOBE=>"M'
MU;5?`?P6T0_;];MM-<P7#Z&LS16LFLRH0-1U_4I$*V]FY:VME260QN8':7D4
MIUI.-K0Z;VTMO;=VZ76K\D==E0@WO)==OZ2W^1^G?PX^#WPV^$^D6VC^!/">
MDZ)';QHDE^EK%-K-_(J*CW.HZO,K75W/(5W-NDV@L0BHN%'3&$8;+7OI?KV]
M3FE.4W[SVZ=/Z\]S:\9?#[P3\0=*N-%\:^%]&\1Z?<1&)HM3LH9IH0>CVEWM
M%Q93J>5EMY8G4\AA3E",E9I/_@$IN.S:L?&W[/7P>F_9[_:'^(?@FPDOKWP5
MXT\$67BCPEJ-S$TDL2Z3K?V2XT74;Q%\M]0L?[2D42'8T\!@E*AV95RIP]E/
ME6TDWWV:MT5M']_X[SDJE)/9Q>JOY=OEY_@S[ZK<YREJ.H6>D:=?ZKJ-Q'::
M?I=E=:A?74IVQ6UG90/<W,\A[)'!$[D^BFDWRKM8:5VDMWL?A;:?&?Q5X?\`
MVI_#?QV\3VUYI>B^.+Z/4-/CN<E9OA5K-Q=>%[!D3@"*WT^Q%PH;.)K(2$`M
M7%[5J?-LGNKV5UYZWT26EKJVAV\B]FX*SLK:=U^MUK>^_?;]W4=)$22)U>-U
M5XW1@R.C`,CHRDAE*D$$'!!XKN.';RL.H`*`/C[X]1._C[22@8LOA?3PNQ2S
M`G6-<!/`/0>Q_2OY,\=U4EQCE<:<)OER>AK%-ZO&X]):+RO\C].X,?)D^)U2
MYL542O\`W:-!OSZIZ:Z%OP9I@NQ'%?>';^ZB;`^UZ;;7%M=1`]68&%K>Y4$=
M&0'C.[&!7F\)96L5[*EC>'L7C*4K)U\'2JTZ\>S_`(<J%72[:G"#>B51&^:5
MW2<IT<?3H2C=*%:<90?;7G4X];6;2?1RN=QKWB6YLM6M?"FF7-S"FG6=NEY?
MRHD6JLMTJ7$.GF91NBAA@>+<!M)8XX"#=]KQ!Q%C,OS3"<,99BZM".6X>G"M
MBZD(TLP<*Z56&"E4BN:%*A#D4HIWE+24N5*_CX#+Z5;#U,SQ%*$GB)R<*2;E
M13@^2591>CE.7,T];*_5L]!T^$0:9]H:]DGR`TMO>2M<PS!0K%94F9N"1UX.
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M*"2G9VBUS.UMY-O?8^_PDX2IQ?M/:7A+5M2U2[^=XV2LM+GZ&1?ZJ/\`ZYI_
MZ"*_T`H?P:/^"/\`Z2C\.J?'/_$_S)*U(/D?]K+7[[4M$\&?`[P[<&+Q+\;O
M$MOX<N&A;,^G>"["2&\\6:FZH=T</V7R;<L1AHY[@#.PXQK-\L::6LVE?HO7
M^MD^QM15N:;5U!77K_P/PNCP#_@H%\(+"V^&'@'QAX<L%@@^&[6?@VZCA0[X
M?"FHPPVFEL[H!B.SU6UM(@>.=6=N_$5XVC%K11TMTVTTM\NVOF70G>4D].;5
M?K_7D?3/[('Q,/Q,^!OA6\N[CS]<\,1'P?KI8YE>[T..**SNI`><W.DO83%C
MG<[R<G!K6E+F@O+IIIV6G9?\%(SJPY)=D]OU]+'T]6AD>+?M&?\`)"/BU_V(
MOB#_`-(9*BK_``Y^C-:/\2/]=&?G/_P3F\1^'?#^K_%!==U[1=$-Y8>%ULUU
M?5;'36NVBN=8\T6RWD\9G*>9'N$>[;YBYQN&>7#64I:I67]?<;5T[1LM(WOY
M;?Y'W3\:?VC_`(=^!O".LVVB^(M+\7^-]4TV]T[PMX0\*7D/B+6M0U>[MWM[
M,R66CO<26UI%+*DLLD@3Y$8)N8@'>I5A&+BGS2::26NNVMMOZL8PI2;5URQB
MU>^G79>9\T_L1?LN^*O`>JS?%SXD63Z)K=QIESIOA?PQ<#;J5C;ZB4_M#6=:
MB!Q8W4T$8@@LR6D1)IVF",4431IN-Y--:Z)[[?\`!:U2[V1I6J)^ZG?N^G?_
M`"OZ>IU'_!1?QC>:'\)/#OA2SE>!/&WBJ.'4C&Q7S]+T"U?5)+1P"`8I-1;3
M'8'.1!C&"<&(;C&*7>_W:?KOT=NI.'C>3>W+M^6W];&W_P`$^/"=IH?P-?Q$
MD*+J'C+Q/JU[=7``WO::/)_8VGP,02=D36UXX&>MTYP-U/#JT.JUVOV[=A5V
M^>VW*M/ZZ'W76YB%`!0`4`?)'[6OB"_OO#WA#X)>')S'XG^.'B6U\+,T3#SM
M/\(6LD-WXLU1E4Y2)++RX"2,,D\W]QL8UKV5..CE^2[V3TV7_`N;T4E>;V@O
MT?Y+]#P']OWX.:?;?"KP#XK\.V(AA^&7V/P=<101Y9/"6HP6]CIYE90,16>I
MVEFH/&#J<I[DB*\$E&2T<?\`@O[[JROI=]V70F^:2V^UIWT7]=K'TG^Q[\3/
M^%F?`WPO<W5QY^N>%4;P=KNYE,IN=$CBCL+J1021]ITA["7<?O,TF.E:497@
MO[NF]^FE]M;;^?W&5:/+/163V_)GU%6ID%`'Q[\?)"GCW257(+>%]/*[3M(V
MZOKF>XP,<9S7\E^._/'C+*I0E*-LGH+1M6MC<<[WOI^G<_3^#%?)L4M%RXJH
M]?.C05_+E:3_`.&UE\&ZA;68CDOM;U")5((L])EGDF<`$8DN'F6WMUY&<%SS
M]WH!Y/"N84,*H5<;G>,I0@E^XP-2;JR::=G5E.-&EYM>UDE=J-]#;,Z4ZW-'
M#X.G.[TG6BE&*6C<8I<\MK*W+VOO;I/&_AC6[S4K7Q;X=LI[B6]L;=M1T,SI
M/JR16HCM[?4%A8AIXY8/)#KDR*P##<"=OU'&7#>;8_'83BC(<'4JU\7A:4L3
MEDJL:N91I4(JE2QRBW&<U6I\G.OXE[22DI/E\_*,PPM"A4R['58PC1G)4\0H
MN%"\VY2H\R347!\]M5%JZ;BTF1Z-)XQU%1:G2=0TNU61?M&H:O!-I]I9Q`JK
M22-=(C2;2N-J*Q)[XR1P97AN+<?_`+/4RS$Y7A:=E7QF/IU,-AL/%NSJ2G4Y
M>:S>D*<9N4K)+733%/+,.U4^L4Z]2S<*5*2J5*DK.T4HIQ5[_$W\SJO%M]9V
M$,.DR7VL:7+8VL$5M<QRM<:;J$*JHCO'BMY@\1E(.7C$F#D%202/J^+,9@<#
M3HY-+&9AE=3`T*=.E6A5E6P6+I*#4*ZA2G"4%55Y.=/GLVXS4FM?.RNE6K.>
M+5*AB8U9R<XRBHU:3N_<YI1?/R[*,N7HU))H^7O$<TKW*A[K[4/-0K,L\DJL
M"\8'^LPRDACD.H/)'U_G[,ZE26-@GB%B(JK&TXU'-/WNJE[\7Y27Z'WF%C&$
M+<G(XP=TTEK:36GET:WOY:?HA%_JH_\`KFG_`*"*_P!`J'\&C_@C_P"DH_#J
MGQS_`,3_`#)*U(/SA\*^&]=_:7^/'Q*^*^C>/?$?@;P[\-+B/X9?#[6_#,&E
M7$^H>3'=-XFG@;6M/NH1;RR3^:7CC#E-3A4/B-A7-'][*<HRY>6R3MJEJM+[
M)K72SN_OZ&U2IQC:_,KM/Y=K/2VGYZ'L?B[]F7QCXN\,ZWX9UG]HGXGZQINK
MV$MK<:9JMAX+?3KMAB6WCO%M_#L<OD"YBA9C%)&XV95@<$4Z,[6]JWY-=M5U
M\NA$*BA)/V:5M]]NN[/B+]@7QQ?>`/C#XJ^$7B$FR'BB.^M%M9CY2VWC'PA+
M<B2$;R!ON-.34XP/O.;.`#/`K*A+DGR-V3LDK[/=*UM^CM9)[F]>-X)[<OZZ
M?Y'[,5V'&>+?M&?\D(^+7_8B^(/_`$ADJ*O\.?HS6C_$C_71GYH?\$_OA[X&
M\?WGQ3LO&_A'P]XKMK33O#0M(M>TJSU/[)]IGUA+@VC743M:O(L<89HBC'RU
MYXKDP\5)RC))I)/7RT_4WK3E!1Y7RZO\+?YG(?M`_"C6_P!D3XQ^'/B-\+UD
ML/"M_J#:IX7<B2>WTJ_B!.L^#=2F;+3:?/:22^4)2S26ES)'N:2U9J=6+I23
MC=1OS+71-625O+_TG3HV.$U5ARR^)*S].C_K9_(_7KX/_%/P]\8_`.B>.O#L
M@6#4(?)U+3V=6N=%UJV54U+2+L#D2P3'*L0OF120S`!9177":G%-:6W5T[/Y
M'+.#INSVZ/R_S75=#X__`."C?A*\U?X4>%?%5I$TL?@[Q<HU$(C,T&G>(;*3
M3OM+$#"Q+J4.F1,3CFY7TK'$+W%K;E_K;KMVWMLKFN'=I-=UI\OZ_JQT?_!/
MCQ99ZW\#'\.),AU#P9XFU:RN[<$>9'::O+_;.GSL./DE:YO4!QUM'&3M)IX=
MKDLOL^5O^'V:OY;"KJTT]DUI\OU_X!]U5N8!0!7N+NTLQ#]JNK>U%Q<16EO]
MHFC@$]W.2L%K#YC+YMQ(P(2-<LQ'`-)M1W:BO/0$NW0L4P/SA\,>'M=_:9^/
M?Q(^*>B>//$7@?PW\+IH_AGX`UOPU!I-S<7\D<5RWB:>!M8L+J`0S27#R&2.
M,2&+4;=-V$(/*E*I4FXRY>6R3MVNK+5>KTW]$WTRM1IQC:[ENGZ*^W9VMJ>R
M>+?V9O&/B[PUK?AG6?VBOBAK&FZQI\UI<:;J=AX*?3[LD"2".[6W\.QR^0+F
M.%F\J2-\)\K*<$7[*:_Y>N271KM\]/5:K<SC447=4TK>OZMGP_\`L%^-K[X>
M?&?Q5\(_$!:SC\4I?:=]EG(C%OXQ\(37>V,!OXKC3EU6+C!=K:V7DX%94)>S
MDZ;T;^Z]MM;6:VTW>G1&U>-X1E:UK/Y-)K]/0_9JNPY`H`^0/VC=-NX?$6@:
MV(V-E/HW]FB55)2.YL+^ZNF21L84O'J,94'KY3X^[7\M^/.7XB.>Y-F$J;>"
MQ6`^JJ:6D:V'Q%>JU)[+FCB8<J=N:S2O9H_2N":]-8+%4$[5:=?VDHWM>G4I
MP@K+?1TI*3Z7CU/*/#VO+I\D<^U998FW01S`/%!(NTK-(C$B380"JE2N>6R!
MM/XQE68O+*T:LJ2G7IZTU*SII[*<HZJ;CO&#:BY)<_.O=E]5B<.JT''6-.6\
MH_%YQTLX]W9WWY;MW/7M+\:R6^GW\[W3R:CK++;-<O)NF6UC/FW;[QSNGE:*
M(8R%$;XXQC]&R[B^O@\!F-=XF<\RSAJA*K.3<XX:#YJ\KMW7M:G)33]U*,*B
M[(^?KY5"I5HTU24:&#]]1@O=Y]535OA2A%-O75M7MJ=+>>/XQ>VT,\S-97>@
MV.FWZ%@`@N+0[[E58G$L-Q)YH)Y(4K@;CCZ7%\<I8[#*O6;P&+RG"X+%1;D[
M1G0UK):ISHU9>UNK-\LE>\M>"EDC]E4E2C^^IXFI5IM+2ZGI!M7?+.%XM=+I
MOX4>4:UXIE-N^EW;>=':R2_9R&#2V4H++)Y$C8_T=V'S1_*O1EPPR?R_,>(:
MTL//+<3)UJ.'E-49/65"=[2]E*[_`'4VO>HW<7=2BHRLSZ'#X&,:JK4X\LIJ
M/-'7EDDO=<EMSK2WVNC]T\YL+>ZU_7-,TRT5IKB^O[:WB5!R6DE1=^.BHB98
MD_=5221S7@95E^)S/-,#@J2=7$8W$4:-**5W>=2*<M+M12O)O913;2Z^EB:U
M/"8:K5G)*-*$IS;V2BFTK]=>BTO9+8_2Y%V(J]=JJOIG:`.GX5_H;"/)"$/Y
M8I?<K'X1)WDWM=MV/B_]JC]J+P/\.?A_XAT#POXLT75_B+KUE=:'I.FZ-J=I
MJ%QH;7:/:WNL:JUG,XTW[)`TIB25DE>?R@J%0Y3.K4C&-KZOYZ)V?1J_2S^=
MC6E2;>JY5&VC6_Y&M^QEJWPTLO@AX$\,^$O%GA_5-=?3KC5O$>EP:I9-KR>(
M;Z:2[UE;[2_/^U(]M(1;AVCVF*TC969"&+H\JA&*LGO;KZV>OSLO1!64^=MQ
M:BMG;2W37;?\>VQ]8:AJ.GZ39SZAJE]9Z9I]JH>YOM0NH+*SMT9UC5I[FX=(
MX5,CHH+,!E@.I%:-J*U?*E\C))O1*[[(_!G]ICQ1X7\(_M177Q`^%?B71-8-
MOJ?ASQD]UH][;7^GV_BBV:-]4L3>6LCPW`G:S26;RF8`:E(A.00.&HU&HW!Z
M+5-/1771KL[M].ECN@I.FE--75M>VWY:=S]@OA/^T/\`"KXOZ3I=WX9\6:-%
MK=_!";GPC?:E:6OB73[YHM\]BVESRI-=^6P?$]NDD;J`ZM@X'7"I&26J36C5
M^OZ^5MSCE3E!O1V6SW5NFO\`PWH>=?M4?&+X9>'OA#\1_#-[XV\-MXGU;P]J
MOA^P\-VNKV5WK<FJ7<7V802Z;:S23V@B9R\CSI&J+&^3N`!56<8PDKI.UDKZ
M]MBZ,)*<7RM):WM96VZ_H?!W_!/OXH^`?`?BCQWIGC+Q3H_AF3Q-IVA)HUUK
M-[!I^GW5QIUUJ!N+5K^X98+>?9>1.@ED0.$?!RN#S8>482=WRMK2^B^_N;5X
MMQCRIMQ;T2_KMV/U,^)W@'PC\>?AEJOA>:^L-2TC7;4W.AZ]IMQ;:C;V.K6;
M2?V;K&GW5N[Q3&WNU97$;D/&9X20':NN<%.+CMV?9G-"3I2VM;=;?FM#\>?@
M+\7/$'[(WQA\0^"OB!%=0>&9]0_L7QMID2R2FRNK4'^R_%FD0`YN4\F2-LQA
MOM-E=*5RT46WDI3]E-Q>B5[]]-M;:VZ;=>MD=<X*I'2UUL_^&^Y_\`_82V\5
M?![X[^%M6\,Z5XK\*^-]$\1Z/<VNI:7IFL65S?C3[A!&\LVGK)]KT^:)WC=7
MF@C:*18VP&`KKO"I&R=T_P!.JOVTUZ,Y+3IM.SBX[.W](_,&V\)?%C]A'XI7
M/BRTTC4_&OP@U3;INJZGI\4DL-]H33M-:IK"1(RZ'XGT\[GAGF"VTS&:-91'
M<L(^:TL/)/>,KK:W;KLO);:>;.F\*T;?#);+JG^J_K1H_43X;_&[X7?%C2[?
M4_!'C#1]2:9%:72);N"TUZPD*@O;W^C3R+<V\J$E20C1L5)1W7D],:D)*Z>V
MZZKU.:5.5/=:+JMCHO%OQ'\!>`M/GU/QCXO\/>'+*VC,KOJFJ6EO*RK_``V]
MH9#/=RG!`C@BD=B,!33<HI?$DEYHE1D[63?1'Y\^'?CJG[47[4GP\T+PU;7,
M'PO^&4VM^,K9KJ-HKG7=;TK3Y+2QUV]M_P#ES@AO+ZV2S@D_>*)))'"M+LCP
M4O:U(V?NPL[6ZV>O79V7ST=VK]')[*D^DY*SV[[+Y;^GE<]L_:F_:@\$?#?X
M?>(M#\,^+-$U;XC:W9W>A:1I>CZG::A=:)+=H]I>ZOJIM)9!IHLH6E9$F*2/
M/Y*JA&YDNI4C%6NK]K]+V=K=>BU7X,BE3ES)M<JCW\MM/Z7KL7?V+=6^&UG\
M#_`WAKPKXK\/ZEX@ELKO5O$NEP:K9-KR>(;V>2YU<7VE^=]J1K?]W`':+:T-
MK$X9E(8E&4%!13BI=4M-=]O);VT5NE@K*7.W9\L;6?2WK;O_`)'UKJ&HZ?I-
MG/J&J7UGIFGVJA[F^U"Y@LK.W1G6-6GN;ATCA4NZ*"S`98#J16S:7DD9)-Z)
M7?9'X-?M.^*/"OA7]J"Y\?\`PM\2:+J[0:CX;\8RW>BW]O?6%OXJM7CDU*U^
MVVLCPSF=K.*:;RF8`ZA*C<[E'!4?)4;C)];:_+\'?[NF[[J46J:4XVT:L^W1
M_I;RZ'[#?"']H#X9?&;1=,OO"OB72EUJ[@!O?"-U?VT'B33+V*V%Q>6LFERN
MD]S%"H=A=01O"\:%U;A@O9&<9)6:3[7^_P!;').E.GNM%U6W_`^=M3VNK,S)
MUS0]+\1Z9=:/K%JEW8W:;9(FRK(RD-'-#(N&AGC<!E=2""/3(/EYQDV79]E^
M(RS-,-'%83$1Y91E\46FG&=.6\*D))2C*-FFENM#IPF+Q&!KT\3A:CIU:;T?
M1KK&2ZQ:T:?X.S/F75?V;[U+IGT#Q);_`&,LQCBU6WE2YA4DX0SV:LD^T$#=
MY<6?3U_GK-?`/'.O+^Q\]P\\*W>,,=2J1JTU>Z7M*"DIVLO>Y87ZH^[PW&]&
M--?6<'4C4TO[)QE"5EORU&FN]GS6Z,K)^S_XQ3C_`(2#0%"C:NW^U!QG/(^S
M@#GG`[FO,_X@-Q2N7ESW+%RKE2:Q>BWLKTGUZO7[SH_UTRM._P!3Q-^ME27X
M^T=U]Q8F^`WC.;;N\1:#\L<<8&-2P%C15'`MQ_=_#-5/P)XKG:^>Y9[L8P_Y
MBWI&/+I>CIH2N,LKBFE@L3J[ZNDUO?5.>K\_\K%%_P!G;Q7<.#<>(M#4?*&V
M)J#X"C:"%:!=[;?4CZTH^`G$KJ)U,\RUVLG/EQ4I*VE^5TXQ<DMKM7:6JU8W
MQME\4XT\)B/G[->J;YY-+R6GD>T?#[X2Z)X$<W_G/JVN-&T1U&>)88[6-P!)
M%8VP9_)W#AI&=W89`*JQ4_KW!'AAE'!]7Z_4K2S7.7%Q6)J05.%"+5I1P]).
M7)S:J524I3E'3W4VG\MG'$6)S2/L(P6%P::?LT^:4FMG.=HWMNHI**=MVDSU
M>OTT^=.!C^%/PN@>62+X;^`HI)Y))IW3P?X>5YI97,DDLKC3LR2,Y)+,2234
MJ,8Z**C;R*YY_P`S^]EW2OAY\/\`0M3CUS0_`_@_1]9BCEBBU?2O#6BZ?J20
MW"".:-+ZSLHYE22,;6`?#+D'@TU&*M9)6VLD#E+5.3\TV^GEY&]K&C:/XATZ
MYT?7M*T[6M)O%1+S3-6LK?4-/NECD2:-;BSNXY(IE6:.-P'0X9%8<@&AI-6:
MNNS\A)N/POE.4A^%7PNMEV6_PW\`P(/X(?!_AZ)1C_933@*.6*Z)6\OO'SS_
M`)GIYLFM/AE\-]/U&TUBP^'W@BQU?3YOM%AJEGX4T*UU&SG",@FM;V"P6:"4
M([C<CJ<,>>:7)%-/E2<=%I_6W3L'/.S7,[/=79'+\+/AC/?7>IW'PZ\"SZE?
MW,U[?:A/X2T":^O+RX<R3W5U=RZ>TL]Q)(S.\CNS,S$DDDFFHQ6R2^0<\U]I
MJVROV&S?"KX7W"[)_AOX!G3^Y-X/\/2+_P!\OIQ%%DNB7R#GFOM-?-G5Z-HF
MC^'--MM'\/Z5IVAZ39"1;/2])LK;3M/M1+*\\HM[.TCCBA#32R2,$09:1F/)
M)H2459+E2V2T_`3;>[NS&U3P%X%UO49-7UKP7X3UC598HH)-3U3P[I&H:@\-
MN"L$3WEW9R2M'&K$*I<A0<#BERQ=G9.VSM^0U*4592<4NB=A-(\`>!/#VI'6
M-`\%^$]#U=K>2U;5-'\.Z/IFH-;3-&TMNU[96<<S0.T,19"Y4F-<C@4U&,=H
MJ-MK)+^MW]XG*3WDW;NSJI(XY8WBEC22*1&CDBD57C>-U*O&Z,"&1E)!4@@@
MD&F+;RL>):_^S5\!?$UVU_K'PI\'2WS,6>\L],72+EF/WF:;2'M6+$]23D\Y
MZU#IP_D7W?GW^9HJM2.BF_S_`#OV(-)_9B_9_P!$N4N['X3>#VNHL>7/J6G'
M6I$Q_=;69;K:,#D#KWI>RIK["7]7^[RV!U:G\VWIT/8-+\/:!H:A-%T/2-'1
M4\M4TO3;+3U$>0?+"VD,8"9`.WIP/2K24=DH^BL1=[7T[?UZ+[CF(_A3\+X7
MFDB^&_@*.2>62>>1?"'A]9)II7,DLLSC3]TDC.Q8LQ))-)1C'112MY#YY+3F
M:MLKLNZ7\._`&A:I'K>B>!O!^CZS#'+%%JVE>&M&T_4HXIT\N>-+ZTLHYE22
M/Y&`?#*2#P2*:C%6M%+EVT6G>W83E)Z.3:[-F_J^C:1K^G7.CZ[I>G:SI-XB
MI>:9JME;:AI]TB.LB+<6=W')%,JR(C@.APR*1R`:&DU9JZ[>@)N.SLT<G#\*
M?A=;+LM_AMX!@0?P0^#O#T2C'3Y4TX"CEBOLI/T7J/GG_,]/-EK3OAQ\/-'U
M6UUW2/`G@W2M;L?/^Q:OIOAG1;#4[7[3;R6ES]GOK6RCFA\VUFFA?:XW)*Z'
M*L0112V25O+MM]P.4GHY-KM=G:4R0H`*`"@`H`*`"@`H`\7^+TLVH?\`"*^#
M]/U"^L-1\0ZL?M$UG?W%DEOH-G$9-7N;U8'42P+$5($F`-CX/4'"J]80[O5>
M76ZTTM?RWTVMT4/=YI=(I:6N[]$EZK7=;71ZCHE]HM[8QIH-_8W]A8;=.1["
MZANX83:1I&+<RPNPWI'Y?!.<$'H:UCRI*,6FHI+?RTV,9*2?O)Q;UU5M_(PO
M%MO:ZN^DZ$GB^Y\,:H^H0:A;P:;?6]OJ.IV]D)'FLQ!(PDEMF4,S%00#$"0P
M4BHJ)2<8\_+)--?+R_(J%X)OV:E&V[7RT?KO^AV$TT-M%)//+'!!"ADEFF=8
MHHHU&6>21R%1`!DDD`5JVDNR1"3>B5WV13T[5M+U>)Y]*U"SU"&-_+>2SN(K
MA$<#(5C$QVDK@C/4$$9!!I1E&7PN]K?\#0;BX637+U1SOCCQI8^!='BU6\@>
M[:XO[73K6TCG@MWFFN6.6,L[!8XHHDDD=CG`3WJ9S5-)VZV73[WT7F53INI*
MR]U+=VV.ATO5]+UJW^U:1J-CJ5LKF)IK"ZANHDE3[T;/"Q"N,CY6P<$''-4F
MGLT[=B91E!ZIQ[75M.AY/\7S+J4G@WPE97U]9WOB+7?*G^Q7MQ;(-%M8@^JR
M7<-NZ^?$J/$5,G"[7QU-8UOLP5[RZ)VTT;\ME;ROMJ;4+04YM:16EUU]=UII
MIKJCU'2-6T+4$DM=$U/3;]-,\NUFBT^\@NOLFQ-L44HAD8Q_*A`SUV$=5.-8
MRB](OFY;?\#RZ=#&2DM9)QYKM75O4UV944LQ"JH+,S$*JJHR22>``!G)JMO*
MQ)E6FNZ+?WUQIMCJEA>7]I!%<W-K:W,4\MO!*Q6*258F;8K$8&:E2BW9/97^
M73^O7LRG"44FXN*O975M433ZMI=I>VNFW.HV-OJ%XKO9V,UU#'=W*1*S2/!;
MNX>555')*J0-C>AH<XIJ/,DWLA<KM>SLNO033=7TK5XY9=)U*QU**WF:WFDL
M+J"Z2&=/O12-`[!7`P<$].:I-=.@Y1E"RDG'2Z3[="-M=T6.ZNK%]7TU+RPM
MC>7MJ]];+/9VJ[=UQ=1-(&@A&Y"7<*`'4GAAE76U]N@<DK+W79[:?,J'Q7X8
M73UU8^(-&73&G:V2_.I6@M'N(SAX$G\W:TR]2@)..<8YI<\$D^9)=-?Z[C5.
M=^7E:>]K6T[Z]#>1TD1)(G5XW57C=&#(Z,`R.C*2&4J000<$'BJ(V\K%*_U3
M3=*A:XU._L["!(Y)6DO+F&W41PKNE8&5UR%7DXSBDVH[M*WZ#46[)*]]B>TN
M[:^M;>]LYH[BTNH8Y[:>([HYH95#QR1MW1E((/H:$TTFMN@.+B[-6:Z%BF(*
M`"@`H`*`"@`H`*`"@#YQMK?3/%WC'QAX\\272+X/\*^9X7L+65MMO?G3RLUZ
M9@"#-`]W(2ML`3<-=11L&";'Y5:5251O]W3T75;:Z:Z:Z[=/,Z_>I1A2C;FE
MJ]=KI=MFMK_W6=_\+O#TND:;K.JSV":._BK6[K7(-%CB6W&DZ?+A-/LWA156
M*?R!YCHJJ%,H3`*$5I1@XJ5UR\TFTO+IIK8RK2UC%._(K7[OKK=WV^^YR'A:
MWTKQ-\3=2\2*8VL=`?4-*\.R2N);K6M5`']O:N9&!>6TM(YX[2$Y$2*\0CPR
MX,04?:MVMRW2O=MM;N[TLDK73TT6[L:3<HTE'NDWO[JTBHVZ7MMON^NFQXP6
M;Q1\1?#'@BXW_P#"/66FR^+-;MAN$6JM;7)M["SNAG$UG'=+`S1D;6,I#9VK
MBIKGJ1IM>[%<S^6B^_;7L]%NYIVA1G4^U=1B^J?E?NKWT>W3<=X%GDUOX@>/
MO$=C\OAY$TSPW92IQ;W]YHRF.ZFMRHV2QPOOC#KD8F4`X%*CK4J3CI#1*VVF
MVGDM/GIH*HN2G2BTU-7=O)Z[;KI^)0U&RL_%'QFLK?R_-M/!&C+J>I&2662%
M]5O@$T^W$,CM%$L4#1SX14W,KELD9#:4JR_Z=K7]%O\`?==$5%RIT>SD[1[V
M=^UGK=]^EM+WL?"JU^TZ_P#$;Q/9)Y&@ZUXA%OI`B01VU\-+,]O<ZE`BX#0R
M2M\L@7#9?DE3A45[U6>RD]%_GTO^._S5;W(TZ;^**U5_A\M-M>FZMYF6ND#Q
M_P#%;6[^[E<>&_!EK%X:6!6\M-3U.=/M&H63,K`F!7EE2<*<NL<<9^5V%3R*
MK6D[^[#2W];:W^[;6[KF5&C%:<TM>MTM+/R:M9>=WT1N^`-&A;QKX_\`%5A;
M6]GHUU<V7A_24M(8X+:[.BP)!J5Y"D0"-"+V,Q*Z`JS)-@Y!S=./OU)6Y8KW
M8I:+31Z?)*Y%1M0I0>Z3EK:^K^;Z==;6\K5-4\8Z3?+XC\0ZW.#X/\)ZA/H^
MG:1&X+>)M>L8XY;N6ZA!_P!*MH97CBM[=@8OEEN9@1&GEISC=RDU[..B6]WJ
MKZ7TM=)/??H.,'#D44U.2NW_`"QO:\>FO>_DMR[\'M.BBTK5==N(K2#7/%&H
M?VUJ=G:JBKIEK=*TND:<410(=ME()_+X8"[!8`MDU1BES/:<M6K;)ZI=GUU7
MZ(5=^]&*VBK+;?KKK?M=OH<A?>&[;QK\8)X88V71?"-L)M>NU=WFU'5-50L=
M+:Y8[T@^S>7`8D8".&UF1=OFYJ'%3K<O2*=WZ_9OY7Z>EM#2,W"BG?5Z1T73
M3MTW^[R/<;#0O#_ANUU+^RK"RT*VNFEOK][&*.TC$BP[7N2$79%Y<29&%"KM
MR!USNHQIIV2BEJ_\V<[E.;C=N36B3]?U>_YGS)IL6G16WBKXLZA8*=)D(T;P
M1HD\9E_MR9)OL]E?Z@LF7U.6>^43-YAD:207$ASY4=<D5RIU7?E3M&+Z\M[7
M>NUGI:UU<ZKS7+13=UK+2UDKNUE?EW>S5OF5I?!T.C:'H7@K4V@_X2/Q=,^O
M>)[J>.)H?"?AN*6.YU!+.-U9+2YF>&&`R1!6DDB,0RHB%"CR15._+*6LG?X4
MG\GJDNOW:E1G+F;CK&-U%)VYI+K?2ZM=+73?0^CO%&O6W@CPQ#+8V\<LBG3M
M#T"PD=DBGOKG9::;;R2'YE@15\R0D@^7`^#NQ73*2I05ELDDMO)::6Z7TT['
M)"///WG9*[D_+KH>,>,QI>H:CIG@&6Z@U35[Z>#5_B!XHN4C;^SM+TMUN[BR
MLI67%BAF18HK6#8(@T4;!I;AR<).%U3;N_MSTT\NRL^G32RN[G134DN>S4+-
M0@M+]$VK^>LG>^NJM<^EH(XH(88H$6*"&*..&-!M6.*-`L:*O\*J@``[`5UJ
MR2MHEL<CO=WWZDM`@H`*`"@`H`*`"@`H`*`.,T_X?>$=+OY=2L](19Y;Z34A
M%+<7=Q90:A*<R7MMIT\[VUO=$X(E2(,N!L*XJ%3@GM_6VVVVAK*M4DK.6B26
MB2V5MTK^O_`1V1`8%2,A@01TR",$<>U69;>5CG/#GA'P]X3@EM]`TV*P2=V>
M9P\L\\A+,X5Y[B1Y/+5F.$W;1DD#)),QA&FK15DO-_J7*<I6N]NFW]?U8EU?
MPSI&MS17-]!,MU!;3V2W5G=W6GW3V%T4:YL);BRFB>6SE:-"T3,1E<K@DDCA
M%N^SM:Z;3MVT_K[D$9RAM:W9I-7VOY-=UJ-NKOP[X*T-6E:RT31M-A\N"%/+
M@C`C1G6WM8009[EPK$(H9W;)Y))I-PI1_E4=E_6[_P"'8)3J/1.3_K[E^!Y#
M\+="TCQ9I&M>*M3F:?5O$^LZE<:K;V.J7-L\&GM.T5IHNI0V5PA\D11,XBD'
M*2KV)SA1IPFI2E=RD]5>VCU5TK;^BVT-ZLI4G&*5HQBK775+XEYVM_E9H]XM
M;6VLK>"SLX(;2UMHDAM[>"-8H8(HP%2.*-`%1%4```"NI)1225DMD<S;;N]6
M<I=?#_PE=V*Z=+I(6T36I/$.R&\OX';6)23->//%<K*SON((+XQ@``*,9^RI
MVY>6RO>VN^W]=BU4G%W3L[6V6W9*VGR.LMK:WLH(;6UACM[:WC6*""%%CBBC
M085$10`J@#M5I**26BCLB&VWJ[LX8?"_P,L.LPKH,"KKS2-J+>?=&5O-F6XD
M6VE,Y:R1ID5BMN8P=H!RJ@#/V--7]V_,[N_K?Y?U<T]M4O%W^';16VM=K9Z?
MUJ[]?I>E:?HME#IVEVD5E96XQ%!$#@>K.[EGED.!EW9F/<FM$E%))64=D9RD
MY.[=W_7W$6F:'I6BMJ#Z991VCZI?S:GJ+HTCO=7T^!+<2O*['<0H`4$*H&%`
M%*,(PORJU]]W^8Y3E))2=U'1>18U'3[/5;"[TR_A\^QOH)+:Z@\R6(302+MD
MB,D#HZJRD@[6!P2.]-I-.+V>C0HMP::T<=O+_AC+F\*>';BWT2TETJW:U\-S
MV]SHEL#*L%A/:1^5;2I"D@25HT^[YHDY)/4DU/LX6BN56CLNGW=?F-3E'FL[
M<U[_`#W(Y_!_ARZ\0Q>*;G3(Y];@MH[2*[FDFD6.*)R\16V:0P>8C'*OY>Y2
M`P(8`T^2/-SVLTK?<[CYY*/(G:*)_$7AG1/%5@NF:[9"]LX[F&[2/S9H&2X@
MW>7(LEO(CCY6=2-V"'((]"4(R5I*Z73\!1E*#O%V=K;)_G<S(/`'A"UU6RUF
M#0[6*_TVRBL+)U\P0P002-+$1;;_`"GN%D9F\YT:3=\Q;<`:GV5-23Y;..W9
M?+;_`(.NY7M9\KC???\`*WDCL:T,PH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
>`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
